First Wave Biopharma, Inc. Appoints Brian Feagan, M.D., to Scientific Advisory Board
December 09, 2021 at 05:30 pm IST
Share
First Wave BioPharma, Inc. announced the appointment of Brian Feagan, M.D., Professor of Medicine, Epidemiology and Biostatistics at Western University and Senior Scientific Director, Alimentiv, Inc., to the company's scientific advisory board, effective December 9, 2021. Dr. Feagan will join Anthony Opipari, M.D., Ph.D.; Richard Marlink, M.D.; and Michael Konstan, M.D., on the First Wave BioPharma SAB. The SAB will work with management to guide and support First Wave BioPharma as it continues to advance its pipeline of development- and clinical-stage programs built around its two gut-restricted GI technologies niclosamide, a small molecule with anti-viral and anti-inflammatory properties, and adrulipase, a recombinant lipase enzyme designed to help with the digestion of fats and other nutrients.
Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for multiple GI conditions, including gastroparesis, and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. The Company also intends to develop Niclosamide, an oral small molecule anti-inflammatory inhibitor therapy for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, and immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.